Publicacións en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (15)

2024

  1. Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study

    Gastroenterologia y Hepatologia

  2. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

2023

  1. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  2. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study

    Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70

  3. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, Vol. 55, Núm. 1, pp. 46-52

2022

  1. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  2. Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2018

  1. Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease

    Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

2016

  1. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease

    Journal of Crohn's and Colitis, Vol. 10, Núm. 6, pp. 657-662

2015

  1. Response to infliximab in Crohn's disease: Genetic analysis supporting expression profile

    Mediators of Inflammation, Vol. 2015

2014

  1. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab

    Human Immunology, Vol. 75, Núm. 1, pp. 71-75

2013

  1. Safety of thiopurines and Anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease

    American Journal of Gastroenterology, Vol. 108, Núm. 3, pp. 433-440

2012

  1. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: A multicentre study

    Alimentary Pharmacology and Therapeutics, Vol. 35, Núm. 2, pp. 275-283